Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/
Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor)
These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the patented technology, it is expected to have a ripple effect on markets worth over $100 billion for finished goods and over $10 billion for packages in the lighting, automotive, and IT sectors.
Philips Lighting brand (currently Signify Group) is the world’s leading lighting company with 2023 annual revenue of approximately $7 billion. The Court ordered Conrad Electronic, the global distributor where these products are sold, to immediately cease the sale of certain products manufactured by affiliates of Philips Lighting brand, and also ordered the recall and destruction of infringing products distributed in the market since March 29, 2017. Additionally, the Court ruled that a fine of up to €250,000 per violation would be imposed for each non-compliance. This serves as a strong punitive measure to prevent the recurrence of such infringement activities. These court orders are applicable to all products with a CRI of 70 or higher, not just those manufactured by the affiliates of Philips Lighting brand. Particularly, by defeating the invalidation lawsuit filed by Philips Lighting, Seoul Semiconductor has strengthened the related patent technology.
For the past 30 years, Seoul Semiconductor has been pursuing its vision of "clean, healthy, and beautiful with light," striving to shift the paradigm from harmful artificial lighting to the light of nature. To achieve this, the company invests nearly $100 million annually, about 10% of its revenue, in research and development (R&D). As a result, Seoul Semiconductor holds an overwhelming number of over 18,000 optoelectronic patents in the LED industry and has collaborated with Mitsubishi Chemical Corporation (MCC) for years on joint research and development to improve CRI.
Chung Hoon Lee, Seoul’s founder and CEO said, “Infringement of intellectual property causes frustration among young entrepreneurs and innovative companies.” He added, “Our investment in preventing technology theft helps to create a fairer market and encourages young people and companies around the world to continue innovating, helping all of us contribute to a better world. This aligns with one of our company's three core missions: honor, trust, and contribution.”
About Seoul Semiconductor
Seoul Semiconductor is the world's third-largest global opto semiconductor (LED) company that has focused solely on LEDs for the past 30 years. Under the vision of "Make the world clean, healthy and beautiful with light" Seoul Semiconductor leads the new paradigm of light with world-first technologies in the fields of lighting, automotive, and IT (backlighting), while Seoul Viosys, a subsidiary, is at the forefront of MicroLED, UV, sensors, and Dacom.
Notable world-first technologies include the innovative no-wire LED "WICOP"; "SunLike," which replicates the full spectrum of natural sunlight; the high-voltage LED "Acrich"; the ultra-bright "nPola" LED, which is more than 10 times brighter than traditional LEDs; the RGB one-chip MicroLED "WICOP Pixel"; and the UV cleaning technology "Violeds."
Seoul Semiconductor holds an overwhelming 18,000 patents in the industry and has won over 100 patent litigations across eight countries in the past 20 years. Believing that the patent system offers hope to young people and serves as a stepping stone to a better world, the company actively engages in intellectual property protection activities. For more details, please visit our official websites (http://www.seoulsemicon.com/en, https://www.seoulviosys.com/en) and social media channels (LinkedIn).
About CRI (Color Rendering Index)
An indicator of how accurately a light source reproduces the colors of objects under natural sunlight. (For example, CRI 70: Designed so that the colors of 14 standard color samples match more than 70% of the colors seen under sunlight.)
View source version on businesswire.com: https://www.businesswire.com/news/home/20241225151382/en/
Contacts
Seoul Semiconductor Co., Ltd.
Jinseop Jung
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Perma-Pipe International Holdings, Inc. Announces $43 Million Contract Award in the Middle East Region10.1.2025 16:23:00 EET | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced it has received a formal letter of award for a development project located in the GCC region. Perma-Pipe will provide thermal insulation, anti-corrosion coatings, and other services from its Abu Dhabi facility. Project commencement is expected to begin in the third quarter of 2025. The value of this project is estimated to exceed $43 million. This project will utilize Perma-Pipe’s anti-corrosion coatings capabilities, fabrication, and the TRACE-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Saleh Sagr, Sr. Vice President for Perma-Pipe’s MENA region, commented, “This award follows the successful execution of numerous development projects in the region. Our differentiated coating solutions have proven to be well-suited for technically challenging projects. We would like to thank our customers for this significant award.” David Mansfield, President and CEO
Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions10.1.2025 16:00:00 EET | Press release
Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings. Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally. A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices. Lenovo Retail Robotics with Yunji offer
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration10.1.2025 15:00:00 EET | Press release
RhyGaze, a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., USA, today announced that it has secured a Series A financing of USD 86 million. The round was led by GV (Google Ventures), alongside Arch Venture Partners, F-Prime Capital and founding investors BioGeneration Ventures and Novartis Venture Fund, who contributed USD 11 million to an earlier seed round. RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, M.D., Ph.D., who is a scientific co-founder of RhyGaze. This funding will enable further development of RhyGaze’s lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness. Activities to be supported include formal pharmacology and toxicology testing, a non-interventional, observational study to assess potential clinical endpoints in patient groups eligi
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore10.1.2025 14:30:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) with best-in-class potential being studied for the treatment of Immunoglobulin A nephropathy (IgAN) and other B cell-mediated diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250110168811/en/ Under the terms of the agreement, Vertex will receive an upfront payment, as well as certain regulatory milestone payments and tiered royalties, on net sales of pove in the region of focus for Zai Lab. Zai Lab will utilize its extensive research and deve
Compass Pathways Announces Pricing of Underwritten Offering10.1.2025 14:01:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares (“ADSs”) and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant (“ADS Warrant”) to purchase one ADS, which has an exercise price of $5.796 per ADS, representing a 40% premium to the last sale price and will be exercisable following a specified data milestone. The offering price is $4.275 per ADS and accompanying ADS Warrant, and $4.2649 per pre-funded warrant and accompanying ADS Warrant. All of the securities are to be sold by Compass. The offering is expected to close on or about January 13, 2025, subject to satisfaction of customary closing conditions. The offering was led by Deep Track Capital and included participation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom